Product Description
Duloxetine is an antidepressant medication that works in the brain. It is approved for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and chronic musculoskeletal pain. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Duloxetine-(Cymbalta))
Mechanisms of Action: SSR Inhibitor,NRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Generalized anxiety disorder | Depressive Disorder | Depressive Disorder, Major | Chronic Pain | Pain Unspecified | Fibromyalgia | Musculoskeletal Pain | Myalgia
Known Adverse Events: Hyperhidrosis | Constipation | Diarrhea
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Chile, China, Hong Kong, New Zealand, Unknown Location
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Depressive Disorder|Depressive Disorder, Major|Vision Disorders
Phase 1: Acute Respiratory Distress Syndrome|Dermatitis, Atopic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HF124-CSP-001 | P3 |
Completed |
Depressive Disorder, Major |
2021-09-22 |
95% |
| HF124-CSP-001 | P3 |
Completed |
Depressive Disorder, Major |
2021-09-22 |
95% |
| HP8825-01 | P1 |
Completed |
Acute Respiratory Distress Syndrome |
2021-02-27 |
53% |
| HP8825-02 | P1 |
Completed |
Acute Respiratory Distress Syndrome |
2021-02-09 |
53% |
| 2017-001599-46 | P3 |
Active, not recruiting |
Vision Disorders |
2019-10-11 |